A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?

Abstract

Get full access to this article

View all access options for this article.

References

Steinberg

Zhao

Heidenreich

et al.

Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65–75.

Owan

Hodge

Herges

et al.

Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259.

Lee

Gona

Vasan

et al.

Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119: 3070–3077.

Ather

Chan

Bozkurt

et al.

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998–1005.

Fonarow

Stough

Abraham

et al.

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768–777.

Gori

Senni

Gupta

et al.

Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 2014; 35: 3442–3451.

Unger

Dubin

Deo

et al.

Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2016; 18: 103–112.

Shah

Katz

Selvaraj

et al.

Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015; 131: 269–279.

Ahmed

Rich

Sanders

et al.

Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007; 99: 393–398.

10.

Damman

Valente

Voors

et al.

Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35: 455–469.

11.

Lewis

Hunsicker

Clarke

et al.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

12.

Brenner

Cooper

de Zeeuw

et al.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

13.

Yusuf

Pfeffer

Swedberg

et al.

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–781.

14.

Massie

Carson

McMurray

et al.

Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456–2467.

15.

Cleland

Tendera

Adamus

et al.

The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–2345.

16.

Pitt

Pfeffer

Assmann

et al.

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383–1392.

17.

Tsujimoto T and Kajio H. Efficacy of renin–angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. Eur J Prev Cardiol 2018; 25: 1268–1277.

18.

Haukoos

Lewis

. The propensity score. JAMA 2015; 314: 1637–1638.

19.

Beldhuis

Streng

Ter Maaten

et al.

Renin–angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction. A meta-analysis of published study data. Circ Heart Fail 2017; 10: e003588–e003588.

20.

Damman

Navis

Smilde

et al.

Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872–878.

21.

Mullens

Abrahams

Francis

et al.

Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589–596.

22.

Klein

Katz

Beussink-Nelson

et al.

Association of chronic kidney disease with chronotropic incompetence in heart failure with preserved ejection fraction. Am J Cardiol 2015; 116: 1093–1100.

23.

Ter Maaten

Damman

Verhaar

et al.

Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 2016; 18: 588–598.

24.

Paulus

Tschope

. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263–271.

25.

Sakata

Yamamoto

Mano

et al.

Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix. J Hypertens 2003; 21: 1737–1745.

26.

Yamamoto

Mano

Yoshida

et al.

ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005; 23: 393–400.

27.

Koumaras

Tziomalos

Stavrinou

et al.

Effects of renin–angiotensin–aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens 2014; 8: 74–82.

28.

Wagenaar

Buikema

Pinto

et al.

Improvement of endothelial dysfunction in experimental heart failure by chronic RAAS-blockade: ACE-inhibition or AT1-receptor blockade?

J Renin Angiotens Aldoster Syst 2001; 2: S64–S69.

29.

Schwartzenberg

Redfield

From

et al.

Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59: 442–451.

30.

Kitzman

Hundley

Brubaker

et al.

A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010; 3: 477–485.

31.

Yip

Wang

et al.

The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008; 94: 573–580.

32.

Parthasarathy

Pieske

Weisskopf

et al.

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail 2009; 11: 980–989.

33.

Agarwal

Briasoulis

Messerli

. Effects of renin–angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev 2013; 18: 429–437.

34.

Fukuta

Goto

Wakami

et al.

Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2016; 23: 78–85.

35.

Tribouilloy

Rusinaru

Leborgne

et al.

Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol 2008; 101: 639–644.

36.

Patel

Fonarow

Kitzman

et al.

Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail 2012; 14: 1179–1188.

37.

Lund

Benson

Dahlstrom

et al.

Association between use of renin–angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012; 308: 2108–2117.

38.

Mujib

Patel

Fonarow

et al.

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med 2013; 126: 401–410.

39.

Philbin

Rocco

Jr Lindenmuth

et al.

Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000; 109: 605–613.

40.

Fukuta

Goto

Wakami

et al.

Effect of renin–angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Heart Fail Rev 2017; 22: 775–782.

41.

Fan

Bian

et al.

Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: a retrospective observational cohort study. Eur J Prev Cardiol 2016; 23: 1421–1428.

42.

Hogg

McMurray

. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 2005; 47: 357–366.

43.

O’Neal

Sandesara

Samman-Tahhan

et al.

Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol 2017; 24: 1212–1219.

44.

Solomon

Zile

Pieske

et al.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387–1395.

45.

Kraigher-Krainer

Shah

Gupta

et al.

Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63: 447–456.